IPUMS PMA: vars by group: fp

Person

FAMILY PLANNING Description	NUTRITION Description
CLIENT EXIT INTERVIEW Description	COVID-19 Description

Service Delivery Point

FAMILY PLANNING

Description

NUTRITION

Description

Infant

MATERNAL AND NEWBORN HEALTH

Description

Use this option if persons are the unit of analysis. Each record represents a household member, including resident women of childbearing age. Variables shown are based on either the household or female questionnaire.

Childbearing age is typically defined as ages 15-49.

Use this option if service delivery providers are the unit of analysis. Each record represents one facility, drawn from the same enumeration areas from which households were sampled.

Service delivery points include hospitals, health centers, clinics, pharmacies, and other facilities that might provide family planning services or products. The questionnaire was completed by a competent staff person at the facility.

Use this option if infants or women who have just given birth are the unit of analysis. Each record represents one infant.

These data are from a Maternal and Newborn Health survey, in which pregnant women are interviewed several times before and after delivery.

Use this option if persons are the unit of analysis. Each record represents a household member, including resident women between age 10 and 49, and young children. Variables shown are based on either the household or female questionnaire.

Use this option if service delivery providers are the unit of analysis. Each record represents one facility, drawn from the same enumeration areas from which households were sampled for the Nutrition surveys.

Service delivery points include hospitals, health centers, clinics, pharmacies, and other facilities that might provide nutrition programming or services. The questionnaire was completed by a competent staff person at the facility.

Use this option if women of childbearing age are the unit of analysis. Each record represents one woman who was interviewed as they were leaving a medical appointment at a surveyed service delivery point.

Use this option if women of childbearing age are the unit of analysis. Each record represents one woman who completed a phone interview about COVID-19.

An "X" indicates the variable is available in that dataset.

Add to cart	Variable	Variable Label	Type	burkf 2014	burkf 2015	burkf 2016a	burkf 2016b	burkf 2017	burkf 2018	burkf 2020	burkf 2021	burkf 2022	condr 2013	condr 2014	condr 2015a	condr 2015b	condr 2015c	condr 2016a	condr 2016b	condr 2017a	condr 2017b	condr 2018a	condr 2018b	condr 2019a	condr 2019b	condr 2020	condr 2020	condr 2021	Variable	condr 2021	cotedi 2017	cotedi 2018	cotedi 2020	cotedi 2020b	cotedi 2021	ethio 2014a	ethio 2014b	ethio 2015	ethio 2016	ethio 2017	ethio 2018	ethio 2019	ethio 2020	ghana 2013	ghana 2014a	ghana 2014b	ghana 2015	ghana 2016	ghana 2017	india 2016	india 2017a	india 2017b	india 2018	india 2020	Variable	india 2021	indon 2015	indon 2016	kenya 2014a	kenya 2014b	kenya 2015a	kenya 2015b	kenya 2016	kenya 2017	kenya 2018	kenya 2019	kenya 2020	kenya 2021	niger 2015	niger 2016a	niger 2016b	niger 2017	niger 2018	niger 2020	niger 2022	nigera 2014a	nigera 2014b	nigera 2015a	nigera 2015b	nigera 2016	Variable	nigera 2017a	nigera 2017b	nigera 2018	nigera 2019a	nigera 2019b	nigera 2019c	nigera 2020a	nigera 2020b	nigera 2021a	nigera 2021b	ugand 2014	ugand 2015a	ugand 2015b	ugand 2016	ugand 2017	ugand 2018	ugand 2019	ugand 2020	ugand 2021
Side Effects (heard) Variables [top]
Add to cart	Variable	Variable Label	Type	BF 14	BF 15	BF 16a	BF 16b	BF 17	BF 18	BF 20	BF 21	BF 22	CD 13	CD 14	CD 15a	CD 15b	CD 15c	CD 16a	CD 16b	CD 17a	CD 17b	CD 18a	CD 18b	CD 19a	CD 19b	CD 20	CD 20	CD 21	Variable	CD 21	CI 17	CI 18	CI 20	CI 20b	CI 21	ET 14a	ET 14b	ET 15	ET 16	ET 17	ET 18	ET 19	ET 20	GH 13	GH 14a	GH 14b	GH 15	GH 16	GH 17	IN 16	IN 17a	IN 17b	IN 18	IN 20	Variable	IN 21	ID 15	ID 16	KE 14a	KE 14b	KE 15a	KE 15b	KE 16	KE 17	KE 18	KE 19	KE 20	KE 21	NE 15	NE 16a	NE 16b	NE 17	NE 18	NE 20	NE 22	NG 14a	NG 14b	NG 15a	NG 15b	NG 16	Variable	NG 17a	NG 17b	NG 18	NG 19a	NG 19b	NG 19c	NG 20a	NG 20b	NG 21a	NG 21b	UG 14	UG 15a	UG 15b	UG 16	UG 17	UG 18	UG 19	UG 20	UG 21
	SEFEARDRY	Side effects concerned about: vaginal dryness	P	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARDRY	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARDRY	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARDRY	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARWEAK	Side effects concerned about: weakness	P	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARWEAK	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARWEAK	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARWEAK	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARWTGAIN	Side effects concerned about: weight gain	P	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARWTGAIN	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARWTGAIN	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARWTGAIN	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARWTLOSS	Side effects concerned about: weight loss	P	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARWTLOSS	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARWTLOSS	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARWTLOSS	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEAROTH	Side effects concerned about: other	P	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEAROTH	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEAROTH	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEAROTH	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARACCU	Side effects concerned about: pills accumulate in body	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARACCU	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARACCU	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARACCU	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARCANCER	Side effects concerned about: cancer/ fibroids	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARCANCER	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARCANCER	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARCANCER	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARDEFORM	Side effects concerned about: deformation of babies	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARDEFORM	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARDEFORM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARDEFORM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARHAIR	Side effects concerned about: increased hair growth	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARHAIR	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARHAIR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARHAIR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARIMPUR	Side effects concerned about: blood build up/impurities	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARIMPUR	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARIMPUR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARIMPUR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARPAIN	Side effects concerned about: pain at insertion site	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARPAIN	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARPAIN	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARPAIN	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARPLEAS	Side effects concerned about: decreased sexual pleasure	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARPLEAS	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARPLEAS	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARPLEAS	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARMOOD	Side effects concerned about: mood swings	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARMOOD	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARMOOD	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARMOOD	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARPTR	Side effects concerned about: partner feels during sex	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARPTR	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARPTR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARPTR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARWEIGHT	Side effects concerned about: weight change	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARWEIGHT	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARWEIGHT	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARWEIGHT	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARREC	Recently concerned about side effects that were not experienced	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARREC	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARREC	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARREC	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECUTCRAMP	Side effects recently concerned about: uterine cramping/lower abdominal pain	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECUTCRAMP	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECUTCRAMP	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECUTCRAMP	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECACCU	Side effects recently concerned about: pills accumulate in body	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECACCU	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECACCU	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECACCU	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECFACE	Side effects recently concerned about: facial spotting	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECFACE	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECFACE	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECFACE	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECCANCER	Side effects recently concerned about: cancer/ fibroids	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECCANCER	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECCANCER	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECCANCER	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Add to cart	Variable	Variable Label	Type	burkf 2014	burkf 2015	burkf 2016a	burkf 2016b	burkf 2017	burkf 2018	burkf 2020	burkf 2021	burkf 2022	condr 2013	condr 2014	condr 2015a	condr 2015b	condr 2015c	condr 2016a	condr 2016b	condr 2017a	condr 2017b	condr 2018a	condr 2018b	condr 2019a	condr 2019b	condr 2020	condr 2020	condr 2021	Variable	condr 2021	cotedi 2017	cotedi 2018	cotedi 2020	cotedi 2020b	cotedi 2021	ethio 2014a	ethio 2014b	ethio 2015	ethio 2016	ethio 2017	ethio 2018	ethio 2019	ethio 2020	ghana 2013	ghana 2014a	ghana 2014b	ghana 2015	ghana 2016	ghana 2017	india 2016	india 2017a	india 2017b	india 2018	india 2020	Variable	india 2021	indon 2015	indon 2016	kenya 2014a	kenya 2014b	kenya 2015a	kenya 2015b	kenya 2016	kenya 2017	kenya 2018	kenya 2019	kenya 2020	kenya 2021	niger 2015	niger 2016a	niger 2016b	niger 2017	niger 2018	niger 2020	niger 2022	nigera 2014a	nigera 2014b	nigera 2015a	nigera 2015b	nigera 2016	Variable	nigera 2017a	nigera 2017b	nigera 2018	nigera 2019a	nigera 2019b	nigera 2019c	nigera 2020a	nigera 2020b	nigera 2021a	nigera 2021b	ugand 2014	ugand 2015a	ugand 2015b	ugand 2016	ugand 2017	ugand 2018	ugand 2019	ugand 2020	ugand 2021
Add to cart	Variable	Variable Label	Type	BF 14	BF 15	BF 16a	BF 16b	BF 17	BF 18	BF 20	BF 21	BF 22	CD 13	CD 14	CD 15a	CD 15b	CD 15c	CD 16a	CD 16b	CD 17a	CD 17b	CD 18a	CD 18b	CD 19a	CD 19b	CD 20	CD 20	CD 21	Variable	CD 21	CI 17	CI 18	CI 20	CI 20b	CI 21	ET 14a	ET 14b	ET 15	ET 16	ET 17	ET 18	ET 19	ET 20	GH 13	GH 14a	GH 14b	GH 15	GH 16	GH 17	IN 16	IN 17a	IN 17b	IN 18	IN 20	Variable	IN 21	ID 15	ID 16	KE 14a	KE 14b	KE 15a	KE 15b	KE 16	KE 17	KE 18	KE 19	KE 20	KE 21	NE 15	NE 16a	NE 16b	NE 17	NE 18	NE 20	NE 22	NG 14a	NG 14b	NG 15a	NG 15b	NG 16	Variable	NG 17a	NG 17b	NG 18	NG 19a	NG 19b	NG 19c	NG 20a	NG 20b	NG 21a	NG 21b	UG 14	UG 15a	UG 15b	UG 16	UG 17	UG 18	UG 19	UG 20	UG 21
	SEFEARRECDEFORM	Side effects recently concerned about: deformation of babies	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECDEFORM	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECDEFORM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECDEFORM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECFERTDELAY	Side effects recently concerned about: delayed return of fertility	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECFERTDELAY	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECFERTDELAY	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECFERTDELAY	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECDIARR	Side effects recently concerned about: diarrhea	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECDIARR	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECDIARR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECDIARR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECHAIR	Side effects recently concerned about: increased hair growth	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECHAIR	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECHAIR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECHAIR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECHEADACHE	Side effects recently concerned about: headaches	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECHEADACHE	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECHEADACHE	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECHEADACHE	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECIMPUR	Side effects recently concerned about: blood build up/impurities	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECIMPUR	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECIMPUR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECIMPUR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECINFECT	Side effects recently concerned about: got infection	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECINFECT	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECINFECT	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECINFECT	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECINFERT	Side effects recently concerned about: infertility/sterility	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECINFERT	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECINFERT	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECINFERT	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECPAIN	Side effects recently concerned about: pain at insertion site	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECPAIN	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECPAIN	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECPAIN	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECIRREG	Side effects recently concerned about: irregular bleeding/spotting	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECIRREG	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECIRREG	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECIRREG	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECBLEEDLESS	Side effects recently concerned about: less or no bleeding	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECBLEEDLESS	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECBLEEDLESS	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECBLEEDLESS	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECPLEAS	Side effects recently concerned about: decreased sexual pleasure	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECPLEAS	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECPLEAS	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECPLEAS	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECLOST	Side effects recently concerned about: method got lost inside body	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECLOST	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECLOST	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECLOST	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECLIBIDO	Side effects recently concerned about: lowered sex drive	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECLIBIDO	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECLIBIDO	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECLIBIDO	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECMOOD	Side effects recently concerned about: mood swings	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECMOOD	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECMOOD	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECMOOD	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECBLEEDMORE	Side effects recently concerned about: heavier bleeding	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECBLEEDMORE	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECBLEEDMORE	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECBLEEDMORE	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECNAUSEA	Side effects recently concerned about: mausea/vomiting	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECNAUSEA	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECNAUSEA	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECNAUSEA	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECOTH	Side effects recently concerned about: other	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECOTH	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECOTH	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECOTH	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECPTR	Side effects recently concerned about: partner feels during sex	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECPTR	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECPTR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECPTR	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECDRY	Side effects recently concerned about: vaginal dryness	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECDRY	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECDRY	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECDRY	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Add to cart	Variable	Variable Label	Type	burkf 2014	burkf 2015	burkf 2016a	burkf 2016b	burkf 2017	burkf 2018	burkf 2020	burkf 2021	burkf 2022	condr 2013	condr 2014	condr 2015a	condr 2015b	condr 2015c	condr 2016a	condr 2016b	condr 2017a	condr 2017b	condr 2018a	condr 2018b	condr 2019a	condr 2019b	condr 2020	condr 2020	condr 2021	Variable	condr 2021	cotedi 2017	cotedi 2018	cotedi 2020	cotedi 2020b	cotedi 2021	ethio 2014a	ethio 2014b	ethio 2015	ethio 2016	ethio 2017	ethio 2018	ethio 2019	ethio 2020	ghana 2013	ghana 2014a	ghana 2014b	ghana 2015	ghana 2016	ghana 2017	india 2016	india 2017a	india 2017b	india 2018	india 2020	Variable	india 2021	indon 2015	indon 2016	kenya 2014a	kenya 2014b	kenya 2015a	kenya 2015b	kenya 2016	kenya 2017	kenya 2018	kenya 2019	kenya 2020	kenya 2021	niger 2015	niger 2016a	niger 2016b	niger 2017	niger 2018	niger 2020	niger 2022	nigera 2014a	nigera 2014b	nigera 2015a	nigera 2015b	nigera 2016	Variable	nigera 2017a	nigera 2017b	nigera 2018	nigera 2019a	nigera 2019b	nigera 2019c	nigera 2020a	nigera 2020b	nigera 2021a	nigera 2021b	ugand 2014	ugand 2015a	ugand 2015b	ugand 2016	ugand 2017	ugand 2018	ugand 2019	ugand 2020	ugand 2021
Add to cart	Variable	Variable Label	Type	BF 14	BF 15	BF 16a	BF 16b	BF 17	BF 18	BF 20	BF 21	BF 22	CD 13	CD 14	CD 15a	CD 15b	CD 15c	CD 16a	CD 16b	CD 17a	CD 17b	CD 18a	CD 18b	CD 19a	CD 19b	CD 20	CD 20	CD 21	Variable	CD 21	CI 17	CI 18	CI 20	CI 20b	CI 21	ET 14a	ET 14b	ET 15	ET 16	ET 17	ET 18	ET 19	ET 20	GH 13	GH 14a	GH 14b	GH 15	GH 16	GH 17	IN 16	IN 17a	IN 17b	IN 18	IN 20	Variable	IN 21	ID 15	ID 16	KE 14a	KE 14b	KE 15a	KE 15b	KE 16	KE 17	KE 18	KE 19	KE 20	KE 21	NE 15	NE 16a	NE 16b	NE 17	NE 18	NE 20	NE 22	NG 14a	NG 14b	NG 15a	NG 15b	NG 16	Variable	NG 17a	NG 17b	NG 18	NG 19a	NG 19b	NG 19c	NG 20a	NG 20b	NG 21a	NG 21b	UG 14	UG 15a	UG 15b	UG 16	UG 17	UG 18	UG 19	UG 20	UG 21
	SEFEARRECWEAK	Side effects recently concerned about: general weakness/pain	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECWEAK	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECWEAK	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECWEAK	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	SEFEARRECWEIGHT	Side effects recently concerned about: weight change	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECWEIGHT	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECWEIGHT	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	SEFEARRECWEIGHT	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	FPSEADVICE	Whose advice most important about side effects	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSEADVICE	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSEADVICE	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSEADVICE	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.
	FPSECFDAU	Spoke with about side effects: daughter	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFDAU	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFDAU	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFDAU	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.
	FPSECFHW	Spoke with about side effects: facility health worker	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFHW	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFHW	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFHW	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.
	FPSECFDAD	Spoke with about side effects: father	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFDAD	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFDAD	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFDAD	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.
	FPSECFFRIEND	Spoke with about side effects: friend	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFFRIEND	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFFRIEND	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFFRIEND	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.
	FPSECFMALREL	Spoke with about side effects: male relative	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFMALREL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFMALREL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFMALREL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.
	FPSECFMOM	Spoke with about side effects: mother	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFMOM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFMOM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFMOM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.
	FPSECFINLAW	Spoke with about side effects: mother-in-law	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFINLAW	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFINLAW	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFINLAW	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.
	FPSECFOTHREL	Spoke with about side effects: other female relative	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFOTHREL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFOTHREL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFOTHREL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.
	FPSECFPHARM	Spoke with about side effects: pharmacist	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFPHARM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFPHARM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFPHARM	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.
	FPSECFSIS	Spoke with about side effects: sister	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFSIS	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFSIS	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFSIS	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.
	FPSECFSP	Spoke with about side effects: spouse	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFSP	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFSP	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFSP	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.
	FPSECFTRAD	Spoke with about side effects: trad healer	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFTRAD	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFTRAD	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFTRAD	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.
	FPSECFOTH	Spoke with about side effects: other	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFOTH	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFOTH	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFOTH	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.
	FPSECFNONE	Spoke with about side effects: no one	P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFNONE	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFNONE	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	FPSECFNONE	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	X	.	.	.

bf	Burkina Faso	burkf
cd	Congo (Democratic Republic)	condr
ci	Cote d'Ivoire	cotedi
et	Ethiopia	ethio
gh	Ghana	ghana
in	India	india
id	Indonesia	indon
ke	Kenya	kenya
ne	Niger	niger
ng	Nigeria	nigera
ug	Uganda	ugand

Data Cart

Your data extract

0	variables
0	samples